Fig. 7: Differential protein abundance analysis in PBMCs from healthy donors and immunotherapy-treated melanoma patients.

a UMAP visualization of 6 samples by sample identifier with labeled cell types (healthy donors n = 3, immunotherapy treated melanoma patients n = 3, biologically independent samples). b Antibody detection per sample. c Differential protein abundance and d differential gene expression analysis by treatment and cell type.